LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Uždarymo kaina

13.35 -0.37

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.96

Max

13.75

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-154M -183M
Pelnas, tenkantis vienai akcijai	-0.6
Darbuotojai	103
EBITDA	-5.3M -37M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+56.6% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-10

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	476M 3.7B
Ankstesnė atidarymo kaina	13.72
Ankstesnė uždarymo kaina	13.35

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-09 23:49; UTC

Rinkos pokalbiai

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026-06-09 23:45; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026-06-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026-06-09 23:35; UTC

Rinkos pokalbiai

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026-06-09 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026-06-09 20:51; UTC

Uždarbis

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-09 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 20:09; UTC

Rinkos pokalbiai

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026-06-09 19:36; UTC

Rinkos pokalbiai

Cattle Climbs as Crude Oil Falls -- Market Talk

2026-06-09 19:32; UTC

Rinkos pokalbiai

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026-06-09 19:25; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026-06-09 19:00; UTC

Rinkos pokalbiai

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026-06-09 18:52; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026-06-09 18:47; UTC

Rinkos pokalbiai

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026-06-09 18:37; UTC

Rinkos pokalbiai

Canada's Cooling Trade With the U.S. -- Market Talk

2026-06-09 18:27; UTC

Rinkos pokalbiai

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026-06-09 17:35; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026-06-09 17:30; UTC

Rinkos pokalbiai

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026-06-09 16:34; UTC

Rinkos pokalbiai

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2026-06-09 15:28; UTC

Rinkos pokalbiai

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026-06-09 15:25; UTC

Rinkos pokalbiai

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

56.6% į viršų

12 mėnesių prognozė

Vidutinis 21 USD 56.6%

Aukščiausias 30 USD

Žemiausias 12 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.